Attention Deficit Hyperactivity Disorder (ADHD) Market Spotlight Report 2021: 10-year Disease Prevalence Forecast, and Licensing and Acquisition Deals, Drug-specific Revenue Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• The publisher estimates that in 2019, there were 179.8 million prevalent cases of attention deficit hyperactivity disorder (ADHD) in people aged 5-44 years worldwide, and forecasts that number to increase to 189.0 million prevalent cases by 2028.
• The worldwide prevalence of ADHD among children aged 5-19 years is estimated to be 5.29%, while the prevalence among adults aged 20-44 years is estimated to be 2.80%.
• Approved drugs in the ADHD space target dopamine, dopamine reuptake, norepinephrine (noradrenaline), norepinephrine (noradrenaline) reuptake/transporter, and the alpha 2 adrenergic receptor. The vast majority of approved therapies are administered via the oral route.
• The highest proportion of industry-sponsored drugs in active clinical development for ADHD are in Phase II, with three drugs in the NDA/BLA stage.
• Therapies in development for ADHD focus on a wide variety of targets. The majority of pipeline drugs for ADHD are administered via the oral route, with one drug being tested in a transdermal formulation.
• High-impact upcoming events for drugs in the ADHD space comprise topline Phase IIa trial results for LSD microdose program, topline Phase III trial results for centanafadine, pivotal efficacy study results for KP484, estimated PDUFA dates for AR19 and KP415, and an expected patent expiration for Adzenys XR-ODT.
• The overall likelihood of approval of a Phase I ADHD asset is 11.8%, and the average probability a drug advances from Phase III is 73.7%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall psychiatry space.
• The distribution of clinical trials across Phase I-IV indicates that the majority of trials for ADHD have been in the late phases of development, with 54% of trials in Phase III-IV, and 46% in Phase I-II.
• The US has a substantial lead in the number of ADHD clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
• Clinical trial activity in the ADHD space is dominated by completed trials. Takeda has the highest number of completed clinical trials for ADHD, with 159 trials.
• Takeda leads industry sponsors with the highest overall number of clinical trials for ADHD, followed by Eli Lilly.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

• Subtypes

TREATMENT

• Non-pharmacological therapy
• Pharmacological therapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

• SPN-812 for ADHD (December 22, 2020)
• ABV-1504 for ADHD (November 9, 2020)
• SPN-812 for ADHD (November 9, 2020)
• AR19 for ADHD (October 8, 2020)
• AR19 for ADHD (October 6, 2020)
• AR19 for ADHD (September 10, 2020)
• Centanafadine for ADHD (June 11, 2020)
• SPN-810 for ADHD (February 25, 2020)
• SPN-810 for ADHD (December 9, 2019)
• SPN-810 for ADHD (November 5, 2019)
• Multiple Drugs for ADHD (September 4, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

• Setbacks For Supernus
• ADHD Advisory Committee Wants FDA-Defined Standards Before Clearing Abuse-Deterrent Stimulant Label
• Gaming For Attention: FDA Grants De Novo For Novel ADHD Treatment
• Lannett Rolls Out US Adderall XR Rival
• KemPharm Seeks Clearance Of D-Methylphenidate Prodrug

PROBABILITY OF SUCCESS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

• Sponsors by status
• Sponsors by phase
• Recent events

BIBLIOGRAPHY

• Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/svpibs

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900